Esophageal Varices

Serum Bile Acid Levels as Early Predictors of Portal Hypertension and Esophageal Varices Post-Kasai in Biliary Atresia

By MedXY 07/13/2026

Serum bile acid levels measured within the first year after Kasai procedure accurately predict portal hypertension and high-risk esophageal varices development within five years in biliary atresia patients, offering a valuable non-invasive prognostic biomarker.

Clinical Updates news

Galectin-3 Inhibition in MASH Cirrhosis: Synthesizing Evidence from the NAVIGATE Trial and Emerging Therapeutics

By MedXY 06/01/2026

This review synthesizes clinical evidence for belapectin in MASH cirrhosis, focusing on its efficacy in preventing esophageal varices as demonstrated in the NAVIGATE trial and early phase 2b data.

Clinical Updates news

Belapectin for the Prevention of Esophageal Varices in MASH Cirrhosis: Insights from the NAVIGATE Phase 2b Trial

By MedXY 06/01/2026

This review synthesizes clinical evidence on belapectin, a galectin-3 inhibitor, highlighting its potential to reduce the incidence of esophageal varices in patients with MASH-related cirrhosis and portal hypertension, particularly at the 2 mg/kg dosage.